Safety and Efficacy of Multi-Target TKI Combined with Nivolumab in Check-Point Inhibitor-Refractory Patients with Advanced NSCLC: a Prospective, Single-Arm, Two-Stage Study
BMC Cancer（2024）
关键词
NSCLC,Checkpoint inhibitor-refractory,Nivolumab,Anlotinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要